Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder

MT Newswires Live

Jan 08

Syntara (ASX:SNT) enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.

The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.

The company expects top-line results from the study in the second quarter, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601387057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601387057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601387057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601387057","market":"us","top_or_hot":-1,"title":"Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder","media":"MT Newswires Live","content":"<html><body><p> Syntara (ASX:SNT) enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.</p><p>The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.</p><p>The company expects top-line results from the study in the second quarter, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyntara Enrolls Final Patient in Drug Candidate Study for Treatment of REM Sleep Behaviour Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-08 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Syntara (ASX:SNT) enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.</p><p>The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.</p><p>The company expects top-line results from the study in the second quarter, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNT.AU","symbol_name":"Syntara Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601387057","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601387057","pubTimestamp":1767831259,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syntara  enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.The company expects top-line results from the study in the second quarter, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNT.AU":"Syntara Ltd","BK7096":"制药","REM":"房地产按揭贷款ETF-iShares"},"translate_title":"Syntara招募最后一名患者参加治疗快速眼动睡眠行为障碍的候选药物研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REM":1.5,"SNT.AU":1},"content_text":"Syntara (ASX:SNT) enrolled its final patient in the Phase 2 clinical trial of its neuro-targeted anti-inflammatory therapy, SNT-4728, for the treatment of REM Sleep Behavior Disorder, according to a Thursday filing with the Australian bourse.The study evaluates the ability of SNT-4728 to reduce inflammation in brain regions linked to the progression of various neurodegenerative disorders, the filing said.The company expects top-line results from the study in the second quarter, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}